A fundamental lack of understanding of Mtb regulation during latent tuberculosis infections (LTBI), which comprises the vast majority of tuberculosis cases, has hindered global eradication efforts. To elucidate mechanisms ...

Mycobacterium tuberculosis (Mtb) is a bacterium causing great morbidity and mortality especially in developing countries. In order to identify possible areas of intervention to positively alter the history of the disease, ...

Despite the global efforts to reduce tuberculosis (TB) rates, the emergence of drug resistant TB has not allowed effective control of this disease. In the last decade, there were roughly 10 million new TB cases per year ...

Tuberculosis (TB) is a bacterial disease of the lung, caused by Mycobacterium tuberculosis, and currently remains an important human pathogen. The only vaccine against tuberculosis licensed for human use is a live, attenuated ...

With the rise of drug resistant strains of Mycobacterium tuberculosis (Mtb) and lags in antimicrobial drug development, it is imperative to explore alternative methods of treatment through host-directed adjunct therapies. ...

Development of new anti-tuberculosis (TB) therapies remains a major priority to combat this infectious disease and to prevent continued transmission of the causative agent Mycobacterium tuberculosis (Mtb). However, newly ...

To view the abstract, please see the full text of the document.

Mycobacterium tuberculosis (Mtb) is the leading cause of death by an infectious agent, and tuberculosis (TB) disease continues to be a prominent global health concern. Infection with Mtb incites granulomatous inflammation, ...

Techniques for pathogen inactivation have been long employed by research laboratories to help ease the financial, physical, and health strains associated with (A)BSL-3 work. While robust protocols exist for many of these ...

To view the abstract, please see the full text of the document.